Vontobel Holding Ltd. Buys Shares of 5,620 Penumbra, Inc. (NYSE:PEN)

Vontobel Holding Ltd. purchased a new position in shares of Penumbra, Inc. (NYSE:PEN - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 5,620 shares of the company's stock, valued at approximately $1,092,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Champlain Investment Partners LLC increased its position in Penumbra by 131.8% during the 1st quarter. Champlain Investment Partners LLC now owns 1,084,595 shares of the company's stock worth $242,060,000 after purchasing an additional 616,700 shares during the period. AQR Capital Management LLC grew its holdings in Penumbra by 439.8% during the second quarter. AQR Capital Management LLC now owns 178,413 shares of the company's stock worth $31,283,000 after acquiring an additional 145,364 shares during the period. Dimensional Fund Advisors LP raised its position in Penumbra by 96.7% in the second quarter. Dimensional Fund Advisors LP now owns 257,058 shares of the company's stock worth $46,257,000 after acquiring an additional 126,392 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Penumbra in the second quarter valued at $17,943,000. Finally, William Blair Investment Management LLC lifted its holdings in Penumbra by 12.2% in the first quarter. William Blair Investment Management LLC now owns 833,703 shares of the company's stock valued at $186,066,000 after acquiring an additional 90,444 shares during the period. 88.88% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Penumbra news, EVP Johanna Roberts sold 600 shares of the business's stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $190.76, for a total transaction of $114,456.00. Following the completion of the sale, the executive vice president now directly owns 60,488 shares in the company, valued at $11,538,690.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Harpreet Grewal sold 166 shares of the business's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $190.83, for a total transaction of $31,677.78. Following the transaction, the director now directly owns 8,697 shares of the company's stock, valued at approximately $1,659,648.51. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Johanna Roberts sold 600 shares of the firm's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $190.76, for a total transaction of $114,456.00. Following the sale, the executive vice president now directly owns 60,488 shares of the company's stock, valued at approximately $11,538,690.88. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 19,368 shares of company stock valued at $3,824,718. 5.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. BTIG Research increased their price target on shares of Penumbra from $224.00 to $234.00 and gave the company a "buy" rating in a report on Monday, October 14th. Royal Bank of Canada lifted their price target on shares of Penumbra from $205.00 to $222.00 and gave the company an "outperform" rating in a research report on Tuesday, October 8th. Leerink Partners initiated coverage on shares of Penumbra in a research note on Tuesday, September 3rd. They issued an "outperform" rating and a $263.00 target price for the company. Stifel Nicolaus began coverage on shares of Penumbra in a research note on Tuesday, September 17th. They set a "buy" rating and a $238.00 price target on the stock. Finally, Wells Fargo & Company downgraded shares of Penumbra from an "overweight" rating to an "equal weight" rating and lowered their price target for the stock from $289.00 to $150.00 in a report on Wednesday, July 31st. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Penumbra presently has an average rating of "Moderate Buy" and a consensus target price of $220.17.

Penumbra Trading Down 0.9 %

Shares of NYSE PEN traded down $1.90 during trading on Monday, hitting $206.75. 225,221 shares of the company traded hands, compared to its average volume of 379,778. The firm has a market capitalization of $8.01 billion, a P/E ratio of 88.04, a P/E/G ratio of 2.41 and a beta of 0.54. The company has a quick ratio of 3.77, a current ratio of 6.25 and a debt-to-equity ratio of 0.02. The company has a 50-day moving average price of $196.52 and a 200-day moving average price of $194.11. Penumbra, Inc. has a 1 year low of $148.00 and a 1 year high of $277.34.

Penumbra (NYSE:PEN - Get Free Report) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.56 by $0.08. The firm had revenue of $299.40 million during the quarter, compared to the consensus estimate of $298.24 million. Penumbra had a return on equity of 8.39% and a net margin of 1.26%. The firm's quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.43 earnings per share. On average, equities analysts predict that Penumbra, Inc. will post 2.59 EPS for the current year.

Penumbra announced that its Board of Directors has authorized a stock repurchase plan on Tuesday, August 13th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the company to purchase up to 2.6% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its shares are undervalued.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.